Reuters logo
Roche suffers setback on cancer drug MetMab
March 3, 2014 / 6:16 AM / 4 years ago

Roche suffers setback on cancer drug MetMab

ZURICH, March 3 (Reuters) - Roche said a committee recommended it halt studies of a development drug, onartuzumab, combined with Tarceva in non-small cell lung cancer because the treatment wasn’t shown to work in late-stage studies.

“We remain committed to helping patients with lung cancer and are studying several investigational medicines in this disease,” Roche Chief Medical Officer and Head of Global Product Development �Sandra Horning said in a statement on Monday.

The halt to the drug, also called MetMab, is a setback for the Basel-based company. Analysts had touted the drug, pending successful completion of trials, as a potential big seller because the treatment options for lung cancers are limited. (Reporting By Katharina Bart; Editing by Maria Sheahan)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below